Rapid exacerbation of neuromyelitis optica after rituximab treatment

Y. Dai; T. Lu; Y. Wang; L. Fang; R. Li; Allan Kermode; W. Qiu

doi:10.1016/j.jocn.2015.08.033

Rapid exacerbation of neuromyelitis optica after rituximab treatment

Y. Dai, T. Lu, Y. Wang, L. Fang, R. Li, Allan Kermode, W. Qiu

Centre for Neuromuscular and Neurological Disorders (Perron Institute)

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

© 2015 Elsevier Ltd. All rights reserved.Studies have shown the efficacy of immunosuppressants against neuromyelitis optica (NMO). Rituximab is recommended as an off-label prescription to treat refractory NMO. However, we describe two such patients who were suboptimally responsive to rituximab and whose symptoms worsened after treatment. Our cautionary cases highlight that in a small proportion of patients with refractory NMO, rituximab may either fail or induce rapid relapse of NMO. This suggests we need to consider new treatment strategies for refractory NMO.

Original language	English
Pages (from-to)	168-170
Number of pages	3
Journal	Journal of Clinical Neuroscience
Volume	26
DOIs	https://doi.org/10.1016/j.jocn.2015.08.033
Publication status	Published - 1 Apr 2016

Access to Document

10.1016/j.jocn.2015.08.033

Cite this

@article{947303d006eb4deab532034cdb4d0318,

title = "Rapid exacerbation of neuromyelitis optica after rituximab treatment",

abstract = "{\textcopyright} 2015 Elsevier Ltd. All rights reserved.Studies have shown the efficacy of immunosuppressants against neuromyelitis optica (NMO). Rituximab is recommended as an off-label prescription to treat refractory NMO. However, we describe two such patients who were suboptimally responsive to rituximab and whose symptoms worsened after treatment. Our cautionary cases highlight that in a small proportion of patients with refractory NMO, rituximab may either fail or induce rapid relapse of NMO. This suggests we need to consider new treatment strategies for refractory NMO.",

author = "Y. Dai and T. Lu and Y. Wang and L. Fang and R. Li and Allan Kermode and W. Qiu",

year = "2016",

month = apr,

day = "1",

doi = "10.1016/j.jocn.2015.08.033",

language = "English",

volume = "26",

pages = "168--170",

journal = "Journal of Clinical Neuroscience",

issn = "0967-5868",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Rapid exacerbation of neuromyelitis optica after rituximab treatment

AU - Dai, Y.

AU - Lu, T.

AU - Wang, Y.

AU - Fang, L.

AU - Li, R.

AU - Kermode, Allan

AU - Qiu, W.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - © 2015 Elsevier Ltd. All rights reserved.Studies have shown the efficacy of immunosuppressants against neuromyelitis optica (NMO). Rituximab is recommended as an off-label prescription to treat refractory NMO. However, we describe two such patients who were suboptimally responsive to rituximab and whose symptoms worsened after treatment. Our cautionary cases highlight that in a small proportion of patients with refractory NMO, rituximab may either fail or induce rapid relapse of NMO. This suggests we need to consider new treatment strategies for refractory NMO.

AB - © 2015 Elsevier Ltd. All rights reserved.Studies have shown the efficacy of immunosuppressants against neuromyelitis optica (NMO). Rituximab is recommended as an off-label prescription to treat refractory NMO. However, we describe two such patients who were suboptimally responsive to rituximab and whose symptoms worsened after treatment. Our cautionary cases highlight that in a small proportion of patients with refractory NMO, rituximab may either fail or induce rapid relapse of NMO. This suggests we need to consider new treatment strategies for refractory NMO.

U2 - 10.1016/j.jocn.2015.08.033

DO - 10.1016/j.jocn.2015.08.033

M3 - Article

C2 - 26704780

SN - 0967-5868

VL - 26

SP - 168

EP - 170

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

ER -

Rapid exacerbation of neuromyelitis optica after rituximab treatment

Abstract

Access to Document

Fingerprint

Cite this